David Mold
Inventor
Stats
- 2 US patents issued
- 6 US Applications filed
- most recent filing
This is official USPTO record data
Details
- 2 US Patents Issued
- 6 US Applications Filed
- 21 Total Citation Count
- Nov 25, 2020 Most Recent Filing
- Nov 21, 2005 Earliest Filing
Work History
| Patent Owner | Applications Filed | Year |
|---|---|---|
| THE JOHNS HOPKINS UNIVERSITY | 2
2 | 2005
2013 |
| Erimos Pharmaceuticals LLC | 2
| 2005
|
Inventor Addresses
| Address | Duration |
|---|---|
| Baltimore, MD | Jun 29, 06 - Jun 29, 06 |
| Baltimore, MD, US | Jun 01, 10 - Dec 24, 24 |
Technology Profile
| Technology | Matters | |
|---|---|---|
| A61K: | PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES | 6 |
| A61P: | THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS | 4 |
Patents / Publication
| Patents / Publication # | Year of Publication / Issued | Title | Citations |
|---|---|---|---|
| 12171729 | 2024 | Formulations of terameprocol and temozolomide and their use in stimulation of humoral immunity in tumors | 0 |
| 2022/0409,552 | 2022 | FORMULATIONS OF TERAMEPROCOL AND TEMOZOLOMIDE AND THEIR USE IN STIMULATION OF HUMORAL IMMUNITY IN TUMORS | 0 |
| 2019/0381,026 | 2019 | IN VIVO AMELIORATION OF ENDOGENOUS ANTI-TUMOR AUTOANTIBODIES TARGETING SURFACE TUMOR ANTIGENS VIA LOW-DOSE P4N | 0 |
| 2019/0111,040 | 2019 | IN VIVO AMELIORATION OF ENDOGENOUS ANTI-TUMOR AUTOANTIBODIES TARGETING SURFACE TUMOR ANTIGENS VIA LOW-DOSE P4N | 1 |
| 9877978 | 2018 | Compositions comprising NDGA derivatives and sorafenib and their use in treatment of cancer | 1 |
We are sorry but your current selection exceeds the maximum number of portfolios (0) for this membership level.
>
Upgrade to our Level for up to -1 portfolios!.